PortfoliosLab logoPortfoliosLab logo
ISIN
US68622V1061
CUSIP
68622V106
IPO Date
Jun 2, 2021

Highlights

Market Cap
$3.52B
Enterprise Value
$3.53B
EPS (TTM)
$0.94
PE Ratio
14.22
Total Revenue (TTM)
$6.16B
Gross Profit (TTM)
$3.27B
EBITDA (TTM)
$1.33B
Year Range
$5.69 - $13.48
Target Price
$11.33
ROA (TTM)
1,892.89%
ROE (TTM)
27,242.52%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

OGN Performance Chart

Organon & Co. (OGN) is up 87.6% since the beginning of the year. At $13 per share, OGN is trading just below its 52-week high of $13. Investors who bought $1,000 worth of OGN shares 5 years ago would now be looking at an investment worth $481.


Loading charts...

S&P 500 Index

Returns By Period

Organon & Co. (OGN) has returned 87.63% so far this year and 43.20% over the past 12 months.


Organon & Co.

1D
0.15%
1M
1.21%
YTD
87.63%
6M
85.05%
1Y
43.20%
3Y*
-8.35%
5Y*
-13.60%
10Y*

Benchmark (S&P 500 Index)

1D
-0.74%
1M
4.90%
YTD
10.35%
6M
10.28%
1Y
26.52%
3Y*
20.83%
5Y*
12.30%
10Y*
13.66%
*Multi-year figures are annualized to reflect compound growth (CAGR)

OGN Monthly Returns History

Based on dividend-adjusted daily data since Jun 2, 2021, OGN's average daily return is -0.01%, while the average monthly return is +0.34%. At this rate, an investment would double in approximately 17.0 years.

Historically, 49% of months were positive and 51% were negative. The best month was Apr 2026 with a return of +121.2%, while the worst month was Oct 2025 at -36.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.

On a daily basis, OGN closed higher 48% of trading days. The best single day was Apr 24, 2026 with a return of +30.9%, while the worst single day was May 1, 2025 at -26.9%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202619.11%-14.43%-17.83%121.20%0.83%0.45%87.63%
20254.29%-2.41%-0.13%-13.16%-28.53%4.99%0.21%-2.68%13.38%-36.80%14.53%-7.00%-50.71%
202415.46%6.17%7.98%-1.01%16.20%-2.95%5.60%3.68%-14.41%-1.83%-14.00%-5.99%9.92%
20237.88%-17.86%-3.96%4.72%-20.22%7.32%5.62%1.15%-20.95%-14.80%-21.54%27.39%-45.12%
20224.79%17.90%-6.43%-7.44%18.37%-11.09%-6.01%-9.25%-17.98%11.88%0.57%7.34%-4.86%
2021-14.18%-4.13%17.79%-3.25%12.08%-19.75%4.17%-12.15%

Benchmark Metrics

Organon & Co. has an annualized alpha of -13.42%, beta of 0.83, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since June 03, 2021.

  • This stock participated in 162.98% of S&P 500 Index downside but only 60.67% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-13.42%
Beta
0.83
0.08
Upside Capture
60.67%
Downside Capture
162.98%

Return for Risk

Risk / Return Rank

OGN ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


OGN Risk / Return Rank: 6363
Overall Rank
OGN Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
OGN Sortino Ratio Rank: 6666
Sortino Ratio Rank
OGN Omega Ratio Rank: 6868
Omega Ratio Rank
OGN Calmar Ratio Rank: 6161
Calmar Ratio Rank
OGN Martin Ratio Rank: 6060
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Organon & Co. (OGN) and compare them to S&P 500 Index.


OGNBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-1.62

Sortino ratioReturn per unit of downside risk

-1.55

Omega ratioGain probability vs. loss probability

1.21

1.41

-0.19

Calmar ratioReturn relative to maximum drawdown

0.91

2.93

-2.02

Martin ratioReturn relative to average drawdown

1.82

13.52

-11.70

Dividends

Dividend History

Organon & Co. provided a 0.60% dividend yield over the last twelve months, with an annual payout of $0.08 per share.


2.00%3.00%4.00%5.00%6.00%7.00%8.00%$0.00$0.20$0.40$0.60$0.80$1.00$1.2020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021
Dividend$0.08$0.34$1.12$1.12$1.12$0.56

Dividend yield

0.60%4.74%7.51%7.77%4.01%1.84%

Monthly Dividends

The table displays the monthly dividend distributions for Organon & Co.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.02$0.00$0.00$0.02$0.00$0.04
2025$0.00$0.28$0.00$0.00$0.02$0.00$0.00$0.02$0.00$0.00$0.02$0.00$0.34
2024$0.00$0.28$0.00$0.00$0.28$0.00$0.00$0.28$0.00$0.00$0.28$0.00$1.12
2023$0.00$0.28$0.00$0.00$0.28$0.00$0.00$0.28$0.00$0.00$0.28$0.00$1.12
2022$0.00$0.28$0.00$0.00$0.28$0.00$0.00$0.28$0.00$0.00$0.28$0.00$1.12
2021$0.28$0.00$0.00$0.28$0.00$0.56

Dividend Yield & Payout


Dividend Yield

Organon & Co. has a dividend yield of 0.60%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.

Payout Ratio

Organon & Co. has a payout ratio of 6.91%, which is below the market average. This means Organon & Co. returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Organon & Co.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Organon & Co. was 82.69%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Organon & Co. drawdown is 59.26%.


Related event

Drawdown

Fall

Recovery

Underwater

2026 bear market2026
-82.69%Mar 2026
4y 28d
4y 3moMar 2022 - now
2021 bear market2021
-23.11%Jun 2021
5d4mo 18d
4mo 23dJun 2021 - Oct 2021
2021 bear market2021
-22.09%Dec 2021
1mo 7d2mo 18d
3mo 25dNov 2021 - Feb 2022
2021 pullback2021
-3.22%Oct 2021
1d5d
6dOct 2021 - Nov 2021
Bear market2022
-0.64%Feb 2022
0s2d
2dFeb 2022 - Mar 2022

Drawdown Indicators


OGNBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-82.69%

-56.78%

-25.91%

Max Drawdown (1Y)

Largest decline over 1 year

-47.96%

-9.10%

-38.86%

Max Drawdown (3Y)

Largest decline over 3 years

-74.10%

-18.90%

-55.20%

Max Drawdown (5Y)

Largest decline over 5 years

-82.69%

-25.43%

-57.26%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-59.26%

-0.74%

-58.52%

Average Drawdown

Average peak-to-trough decline

-43.15%

-10.72%

-32.43%

Ulcer Index

Depth and duration of drawdowns from previous peaks

23.81%

1.97%

+21.84%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Organon & Co. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Organon & Co. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for OGN, comparing it with other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/E ratio of 14.2. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for OGN relative to other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/S ratio of 0.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for OGN in comparison with other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/B value of 3,901.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with OGN

Add Organon & Co. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with OGN